+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 30 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the overall survival of pasritamig JNJ-78278343, alone or combined with JNJ-87189401, compared to placebo in men with metastatic castration-resistant prostate cancer mCRPC, a cancer that has spread beyond the prostate and no longer responds to hormone therapies. This Phase 3 trial aims to assess these treatments alongside best supportive care BSC to improve outcomes in late-line mCRPC. Participants receive study treatments through intravenous infusions, including two step-up doses of pasritamig or placebo followed by the target dose. In Part 2, some participants also receive JNJ-87189401 with pasritamig. Treatments continue until disease progression, intolerable side effects, death, withdrawal, or study end. All participants may receive BSC, which includes palliative radiation, steroids, pain medications, bone agents, and related procedures as needed. During the study, participants are monitored for survival, disease progression, symptoms, pain, fatigue, and side effects for up to 2 years and 8 months. Assessments include clinical labs and quality-of-life questionnaires. Researchers track adverse events and laboratory abnormalities to evaluate safety. The study supports ongoing care while measuring the impact of these treatments in advanced prostate cancer.

Age: 18Years +MALEPhase 3
176 locations
C

Actively Recruiting

Researchers are comparing the effectiveness of two combinations of drugs, teclistamab with daratumumab and lenalidomide Tec-DR, and talquetamab with daratumumab and lenalidomide Tal-DR, against the combination of daratumumab, lenalidomide, and dexamethasone DRd in adults with newly diagnosed multiple myeloma who are not candidates for stem cell transplant. This Phase 3 trial focuses on evaluating treatment outcomes and survival rates over an extended period. Participants will be randomly assigned to one of three groups one receiving teclistamab by subcutaneous injection combined with daratumumab and oral lenalidomide another receiving talquetamab by subcutaneous injection combined with daratumumab and lenalidomide and the third receiving daratumumab by subcutaneous injection along with oral lenalidomide and dexamethasone, which may be given orally or intravenously. Treatments will be administered according to protocol, with close monitoring throughout the study. During the study, participants will undergo regular evaluations over up to nine years, including assessments of disease progression, survival, response to treatment, and quality of life using various questionnaires. Safety will be monitored through laboratory tests, physical exams, vital signs, electrocardiograms, and tracking of any adverse events. Researchers will also measure drug concentrations and immune responses to the study drugs. Participation may last until disease progression, death, or the end of the study period.

Age: 18Years +All GendersPhase 3
270 locations
R

Actively Recruiting

Researchers are evaluating the effects of PKN605, an oral medication, in adults with atrial fibrillation to see if it reduces the time spent in atrial fibrillation. This randomized, placebo-controlled, double-blind study aims to assess the treatments efficacy, safety, tolerability, and how the drug behaves in the body. The study is sponsored by Novartis Pharmaceuticals and focuses on participants with a history of atrial fibrillation. Participants will first undergo a screening period lasting up to 90 days to confirm eligibility. Once enrolled, they will be randomly assigned to receive either a lower or higher dose of oral PKN605 or a matching placebo. The treatment phase will last 24 weeks, with monthly clinic visits. Atrial fibrillation will be monitored throughout the study using various ECG devices. After treatment ends, there will be a final safety follow-up visit about one month later. During the study, participants will have regular assessments including ECG patch monitoring to measure atrial fibrillation burden, blood tests for drug levels, and other safety evaluations. Researchers will measure the time spent in atrial fibrillation and the time to first recurrence of atrial fibrillation after treatment begins. The total participation time includes screening, 24 weeks of treatment, and a safety follow-up visit approximately one month after treatment completion.

Age: 18Years +All GendersPhase 2
40 locations
B

Actively Recruiting

Researchers are collecting real-world data to evaluate the effectiveness and safety of new systemic treatments such as biologics and Janus kinase inhibitors in patients with atopic dermatitis. The BioDay Registry also studies the impact of these treatments on related allergic conditions like food allergies, asthma, and conjunctivitis. This observational registry gathers information from multiple centers to better understand treatment outcomes in daily clinical practice. Participants include both adults and children receiving new systemic therapies for their atopic dermatitis. There is no assigned treatment in the study since it is observational instead, data is collected as patients receive their prescribed medications. The registry includes modules for atopic comorbidities and monitors patients over time to capture the effects of treatment in routine care. Participants will provide data through questionnaires and clinical assessments at multiple timepoints, including baseline, 16 weeks, 1 year, 2 years, and annually up to 5 years. Researchers track changes in disease symptoms, side effects, drug continuation rates, laboratory results, comorbid conditions, and any dose adjustments. This long-term follow-up aims to improve understanding of treatment safety and effectiveness in everyday settings.

Age: 0Years +All Genders
14 locations
P

Actively Recruiting

This trial investigates treatment options for adults aged 16 to 69 with early-stage classical Hodgkin lymphoma, specifically stage I or II supradiaphragmatic disease without mediastinal bulk or B symptoms. The study compares two chemotherapy regimens ABVD and A2VD, using a PET response-adapted design to adjust therapy based on treatment response. It is a phase III, randomized, open-label trial conducted internationally and sponsored by University College London and Canadian Cancer Trials Group. Participants will be randomly assigned to receive either ABVD chemotherapy doxorubicin, bleomycin, vinblastine, and dacarbazine or A2VD chemotherapy doxorubicin, brentuximab vedotin, vinblastine, and dacarbazine with growth factor support. After two 28-day cycles, a PET-CT scan will assess response using the Deauville score to guide further treatment. Patients with scores 1-3 receive one more cycle those with score 4 receive two more cycles followed by involved site radiotherapy patients with score 5 discontinue trial treatment and receive alternative therapy as determined by their clinician. Throughout the study, participants undergo PET-CT scans and clinical assessments to monitor treatment response and safety. They will be followed for at least five years post-treatment to evaluate progression-free survival and other outcomes such as event-free survival, overall survival, and incidence of second cancers or cardiovascular disease. Safety and toxicity are monitored from treatment start until 30 days after completion. The overall study period extends until 2032.

Age: 16Years - 69YearsAll GendersPhase 3
72 locations
S

Actively Recruiting

Researchers are studying patients with non-metastatic stage II colon cancer who are part of the Dutch ColoRectal Cancer cohort PLCRC and who consented to additional blood samples. The study aims to evaluate how many patients with detectable circulating tumor DNA ctDNA after surgery begin adjuvant chemotherapy. This observational and interventional trial includes patients who do not have a standard indication for chemotherapy and involves a randomized design to compare ctDNA-guided treatment with standard care. Patients are randomly assigned to one of two groups the ctDNA-based treatment group or the standard care group. In the ctDNA group, blood samples taken after surgery are analyzed for ctDNA. Those with detectable ctDNA are offered 3 months of adjuvant chemotherapy using CAPOX a combination of fluoropyrimidine and oxaliplatin. Patients without detectable ctDNA receive routine follow-up care. The standard care group receives routine follow-up without knowledge of their ctDNA results. Participants will have blood collected before surgery, after surgery, and during follow-up. Researchers will monitor who starts chemotherapy within 8 to 12 weeks after surgery and will track recurrence rates, disease-free survival, overall survival, time to recurrence, quality of life, and cost-effectiveness over several years. Follow-up assessments occur up to 10 years, allowing detailed long-term evaluation of treatment impact and patient outcomes.

Age: 18Years +All GendersPhase Not Applicable
29 locations
A

Actively Recruiting

Researchers are evaluating whether adjuvant chemotherapy can prevent disease recurrence in patients with high-risk rectal cancer who have detectable circulating tumor DNA ctDNA after surgery. This trial focuses on improving disease-free survival by identifying patients at high risk of recurrence using ctDNA as a biomarker. The study is a randomized controlled trial conducted within a larger colorectal cancer cohort, aiming to clarify the benefit of adjuvant chemotherapy for this group of patients. Participants with detectable ctDNA after surgery are randomly assigned to either receive standard care or adjuvant chemotherapy, which involves 6 cycles of FOLFOX every 2 weeks or 4 cycles of CAPOX over 3 months. Chemotherapy is initiated within 8 to 12 weeks after surgery. The control group receives standard care without additional chemotherapy. The study also examines ctDNA clearance and its relationship with recurrence and survival. During the trial, participants will have blood samples taken regularly for ctDNA measurement and will complete quality of life questionnaires at multiple time points up to 4 years. Researchers will monitor disease-free survival and overall survival for up to 5 years. Safety is monitored through regular physician visits and blood tests during chemotherapy cycles. The total participation duration may last up to 10 years, including extended follow-up for survival and quality of life assessments.

Age: 18Years +All GendersPhase 3
25 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
F

Actively Recruiting

Researchers are evaluating the feasibility and safety of a ventilation strategy called permissive lung-protective ventilation in adult critically ill patients who require invasive mechanical ventilation due to acute hypoxemic respiratory failure. This pilot trial aims to inform the design of a future larger randomized clinical trial by comparing permissive lung-protective ventilation with conventional lung-protective ventilation. The study focuses on how lowering the respiratory rate may reduce ventilation intensity while managing carbon dioxide levels safely. Participants are randomly assigned to one of two groups one group receives permissive lung-protective ventilation where the respiratory rate is gradually reduced based on blood gas analysis and continuous monitoring, allowing mild increases in carbon dioxide levels within safe limits. The other group receives conventional lung-protective ventilation with standard respiratory rates targeting normal carbon dioxide and pH levels. Blood gas analyses are performed frequently to monitor patient status until ventilator weaning or extubation. Throughout the study, participants undergo regular assessments including arterial blood gas tests, continuous end-tidal CO2 monitoring, and data collection on ventilation parameters and outcomes. Researchers measure the feasibility of reducing respiratory rate, adherence to the protocol, safety indicators such as hypercapnia and hypoxemia, and ventilator-associated complications. Data collection continues up to 90 days for follow-up, with the primary evaluation lasting from ventilation start until first extubation, up to 28 days.

Age: 18Years +All GendersPhase Not Applicable
5 locations
R

Actively Recruiting

The trial investigates chronic pelvic pain caused by endometriosis, a chronic inflammatory condition affecting about 10% of women of reproductive age. This disease often leads to severe pain, reduced quality of life, depression, and economic impact. The study aims to assess how esketamine, a drug with pain-relieving, anti-inflammatory, and antidepressant properties, compares to placebo in treating this chronic pain through a randomized controlled design. Participants will receive either an esketamine infusion or a placebo saline infusion. The esketamine dosing begins at 0.1 mgkgh and may be increased gradually every few hours over an 8-hour period up to a maximum of 0.5 mgkgh based on monitored vital signs and side effects. The placebo group will receive an 8-hour saline infusion. This treatment phase is followed by scheduled assessments to evaluate the effects. Participants will be monitored for pain levels, side effects, quality of life, depressive symptoms, and pain coping ability before and after treatment. Assessments occur at baseline and at multiple time points up to 12 weeks after infusion, including evaluations of pelvic pain, menstrual pain, urinary and bowel pain, depressive symptoms, and overall quality of life. Safety and treatment experiences are also recorded during and immediately after infusion. The total study duration includes follow-up visits to track ongoing effects and costs related to productivity and medical care.

Age: 18Years - 50YearsFEMALEPhase 3
1 location

1-10 of 30

1